Which has grown faster, NTLA or PSNL?

Over the past five years, NTLA grew revenue faster — NTLA at a 7.31% CAGR versus PSNL at -3.33%.

How have NTLA and PSNL total returns compared?

Over the past 5 years, NTLA delivered -37.13% and PSNL delivered -1.75% annualized total return. Past performance doesn't predict future results.

Intellia Therapeutics, Inc. (NTLA) vs Personalis, Inc. (PSNL)

A side-by-side comparison of Intellia Therapeutics, Inc. and Personalis, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

NTLA

Intellia Therapeutics, Inc.

$1.71B

$12.24HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT

PSNL

Personalis, Inc.

$1.71B

$16.01HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT

Total return — NTLA vs PSNL

growth of $100 · dividends reinvested · last 7y

NTLA -15.2% (-2.3%/yr)PSNL -42.4% (-7.6%/yr)NTLA compounded faster over this window

NTLA PSNL

NTLA vs PSNL: by the numbers

•NTLA is the larger company ($1.71B vs $1.71B market cap).
•Both run net losses; PSNL's is the smaller (-153.84% vs -672.16% net margin).
•NTLA grew revenue faster over the past five years (7.31% vs -3.33% CAGR).

Metrics side by side

Valuation

Metric	NTLA	PSNL
P/S ratio	28.74	24.52
P/B ratio	2.35	7.27

Profitability

Metric	NTLA	PSNL
Gross margin	76.47%	22.65%
Operating margin	-651.67%	-126.43%
Net margin	-672.16%	-153.84%
ROE	-54.96%	-45.58%
ROIC	-54.45%	-42.87%

Growth (annualized)

Metric	NTLA	PSNL
Revenue CAGR (5Y)	7.31%	-3.33%
Total return CAGR (5Y)	-37.13%	-1.75%

Frequently asked

Which has grown faster, NTLA or PSNL?: Over the past five years, NTLA grew revenue faster — NTLA at a 7.31% CAGR versus PSNL at -3.33%.
How have NTLA and PSNL total returns compared?: Over the past 5 years, NTLA delivered -37.13% and PSNL delivered -1.75% annualized total return. Past performance doesn't predict future results.

Go deeper

Full NTLA analysis Full PSNL analysis Interactive comparison tool

Dig into the metrics

Intellia Therapeutics ROE Personalis ROE Intellia Therapeutics operating margin Personalis operating margin Intellia Therapeutics revenue growth Personalis revenue growth Intellia Therapeutics free cash flow Personalis free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.